rs1

RS1-PDK1 inhibitor (RS 1) is a selective inhibitor of the protein kinase PDK1 that can be used to treat and prevent disease or disorders.

RS-1 is a RAD51 activator. RS-1 also increases CRISPR/Cas9-mediated knock-in efficiencies.

Ginsenoside Rs1, extracted from the root of Panax ginseng [1], is a chemical compound with potential pharmacological properties.

Ginsenoside Rs1 (Standard) is a reference standard for research and analysis in studies involving Ginsenoside Rs1. Ginsenoside Rs1, extracted from the root of Panax ginseng [1], is a chemical compound with potential pharmacological properties.

MRS1845 is an ORAI1 inhibitor and calcium entry (SOCE) blocker that blocks VP-induced SOCE, OS, and Ca(2+) deposition.

RS102895 hydrochloride is a potent antagonist of CCR2(IC50 of 360 nM).

MRS1177 is an effective and selective antagonist of the human Adenosine A3 receptor (hA3AR) (Ki: 0.3 nM).

MRS1186 is an effective and selective antagonist of the human Adenosine A3 receptor (Ki: 7.66 nM).

RS14203, an orally active inhibitor of type IV cyclic nucleotide phosphodiesterase (PDE IV), has the capability to induce emesis.

RS130-180 is a β-arrestin-biased agonist that selectively targets the 5-hydroxytryptamine 2A receptor (5-HT2aR). It shows promise for research in neuropsychiatric disorders such as depression.

VARS1-IN-1 is a valyl-tRNA synthetase (VARS1) inhibitor with a Kd value of 0.213 μM. It suppresses the aminoacylation activity of VARS1, decreases the charging level of valine tRNA, and reduces the overall protein synthesis rate. Additionally, VARS1-IN-1 inhibits the growth and cell proliferation of aggressive tumors in PC3 prostate cancer xenograft models, making it a valuable tool in prostate cancer research.

VARS1-IN-2 (Compound 2901) is a specific inhibitor of VARS1 with a Kd of 0.014 µM. It does not affect VARS1 expression at the mRNA or protein levels. The compound exhibits anti-prostate cancer activity primarily by disrupting the tRNA aminoacylation activity of VARS1, rather than altering its expression.

DHRS11-IN-1 is an inhibitor of the short-chain dehydrogenase/reductase family member 11 (DHRS11), with an IC50 value of 0.037 μM. It binds to DHRS11 and forms a hydrogen bond with the His210 residue of the enzyme. DHRS11-IN-1 suppresses androgen receptor mRNA and protein expression, reduces c-Myc levels, and inhibits cancer cell proliferation. It also impedes the PI3K/AKT signaling pathway by decreasing the phosphorylation of PDK1, AKT, mTOR, and ERK. Additionally, DHRS11-IN-1 enhances Capivasertib-induced cytotoxicity and apoptosis (apoptosis). This compound can be applied in studies related to luminal androgen receptor-positive triple-negative breast cancer.

MRS1220, a selective and potent antagonist for the human A3 adenosine receptor (hA3AR) with a dissociation constant (Ki) of 0.59 nM, exhibits therapeutic promise for central nervous system disease research. It effectively diminishes glioblastoma tumor size and inhibits blood vessel formation in vivo.

RS100329 hydrochloride is an antagonist of α1A-adrenergic receptor.

MRS1067 is an antagonist of A3 adenosine receptor.

MRS1097 is a selective antagonist A3 adenosine receptor.

MRS1041 is a bioactive chemical.

MRS1042 is a bioactive chemical.

MRS1062 is a bioactive chemical.

MRS1065 is a bioactive chemical.

MRS1066 is a bioactive chemical.

MRS1084 is a bioactive chemical.

MRS1086 is a bioactive chemical.